JP2017530692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530692A5 JP2017530692A5 JP2017506267A JP2017506267A JP2017530692A5 JP 2017530692 A5 JP2017530692 A5 JP 2017530692A5 JP 2017506267 A JP2017506267 A JP 2017506267A JP 2017506267 A JP2017506267 A JP 2017506267A JP 2017530692 A5 JP2017530692 A5 JP 2017530692A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cancer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 68
- 239000000427 antigen Substances 0.000 claims 65
- 102000036639 antigens Human genes 0.000 claims 65
- 108091007433 antigens Proteins 0.000 claims 65
- 210000004027 cell Anatomy 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 claims 11
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 230000001613 neoplastic effect Effects 0.000 claims 10
- 230000011664 signaling Effects 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 108010002352 Interleukin-1 Proteins 0.000 claims 6
- 102000000589 Interleukin-1 Human genes 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 5
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 102000046828 human IL1RAP Human genes 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
- 208000035690 Familial cold urticaria Diseases 0.000 claims 2
- 102000018297 Immunoglobulin subtype Human genes 0.000 claims 2
- 108050007411 Immunoglobulin subtype Proteins 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 230000009260 cross reactivity Effects 0.000 claims 2
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 claims 1
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241001442654 Percnon planissimum Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003068 molecular probe Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 claims 1
- 201000002526 pancreas sarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000004593 pneumococcal meningitis Diseases 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1413913.3 | 2014-08-06 | ||
| GBGB1413913.3A GB201413913D0 (en) | 2014-08-06 | 2014-08-06 | Novel antibodies and uses thereof |
| PCT/EP2015/068208 WO2016020502A1 (en) | 2014-08-06 | 2015-08-06 | Novel antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530692A JP2017530692A (ja) | 2017-10-19 |
| JP2017530692A5 true JP2017530692A5 (en:Method) | 2018-08-30 |
| JP6827411B2 JP6827411B2 (ja) | 2021-02-10 |
Family
ID=51587804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506267A Active JP6827411B2 (ja) | 2014-08-06 | 2015-08-06 | 新規の抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10100119B2 (en:Method) |
| EP (1) | EP3193926B1 (en:Method) |
| JP (1) | JP6827411B2 (en:Method) |
| KR (1) | KR20170039685A (en:Method) |
| CN (1) | CN107074946B (en:Method) |
| AU (1) | AU2015298852A1 (en:Method) |
| BR (1) | BR112017002342A2 (en:Method) |
| CA (1) | CA2955056A1 (en:Method) |
| GB (1) | GB201413913D0 (en:Method) |
| MX (1) | MX2017001599A (en:Method) |
| WO (1) | WO2016020502A1 (en:Method) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| CA2824719C (en) | 2011-01-19 | 2020-06-02 | Cantargia Ab | Anti-il1rap antibodies and their use for treating solid tumours |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US10093730B2 (en) | 2014-11-10 | 2018-10-09 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| CN111202915A (zh) * | 2016-04-19 | 2020-05-29 | 南京中硼联康医疗科技有限公司 | 用于消除β淀粉样蛋白沉积斑块的中子捕获治疗系统 |
| EP3241845A1 (en) * | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| AU2017343784A1 (en) * | 2016-10-16 | 2019-08-29 | Cantargia Ab | Anti-IL1-RAP antibodies |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| IL313695A (en) | 2017-02-10 | 2024-08-01 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| EP3401332A1 (en) * | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| CN118994394A (zh) * | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| SG11202000073XA (en) | 2017-07-24 | 2020-02-27 | Regeneron Pharma | Anti-cd8 antibodies and uses thereof |
| KR20200038490A (ko) * | 2017-08-01 | 2020-04-13 | 시티 오브 호프 | 항-il1rap 항체 |
| EP3489259A1 (en) * | 2017-11-23 | 2019-05-29 | Etablissement Français du Sang | Anti-il-1rap-car-t cells and their use |
| CN111971397A (zh) * | 2018-02-14 | 2020-11-20 | 耶鲁大学 | 用于调节trem或treml蛋白的组合物及其使用方法 |
| CN112638946A (zh) * | 2018-08-16 | 2021-04-09 | 坎塔吉亚有限责任公司 | 抗il1rap抗体组合物 |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| WO2021148884A1 (en) * | 2020-01-24 | 2021-07-29 | Tychan Pte. Ltd. | Anti-wuhan coronavirus antibodies |
| JP7767298B2 (ja) | 2020-03-13 | 2025-11-11 | ジェネンテック， インコーポレイテッド | 抗インターロイキン－３３抗体及びその使用 |
| AU2021251269A1 (en) * | 2020-04-10 | 2022-11-17 | Provincial Health Services Authority | Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein |
| PE20231575A1 (es) | 2020-09-14 | 2023-10-04 | Ichnos Sciences SA | Anticuerpos que se unen a il1rap y usos de estos |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| MX2023013714A (es) | 2021-05-21 | 2024-01-16 | Leo Pharma As | Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1). |
| US12252512B2 (en) | 2022-07-25 | 2025-03-18 | Interius Biotherapeutics, Inc. | Mutated polypeptides, compositions comprising the same, and uses thereof |
| US12054552B2 (en) | 2022-09-21 | 2024-08-06 | Sanofi Biotechnology | Humanized anti-IL-1R3 antibody and methods of use |
| AU2024216919A1 (en) * | 2023-02-09 | 2025-08-07 | City Of Hope | Anti-il1rap antibodies and variants thereof |
| EP4687976A1 (en) * | 2023-03-24 | 2026-02-11 | Paragon Therapeutics, Inc. | Fc fragments that bind fcrn and methods of use |
| WO2025126157A1 (en) * | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
| WO2025201513A1 (zh) * | 2024-03-29 | 2025-10-02 | 珠海丹序生物制药有限公司 | 抗il1rap抗体及其用途 |
| WO2026022232A1 (en) | 2024-07-24 | 2026-01-29 | Almirall, S.A. | Il-1rap inhibitor for treating or preventing hidradenitis suppurativa |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US20030215453A1 (en) | 2002-05-14 | 2003-11-20 | Dedera Douglas A. | Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| PL2213683T3 (pl) | 2004-08-04 | 2013-10-31 | Mentrik Biotech Llc | WARIANTY REGIONÓW Fc |
| CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| US8709715B2 (en) | 2008-03-26 | 2014-04-29 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| CA2824719C (en) * | 2011-01-19 | 2020-06-02 | Cantargia Ab | Anti-il1rap antibodies and their use for treating solid tumours |
| CN103077969B (zh) | 2011-10-26 | 2016-03-30 | 中国科学院微电子研究所 | 一种mos器件及其制造方法 |
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| SG11201803675RA (en) | 2015-11-02 | 2018-05-30 | Janssen Pharmaceutica Nv | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof |
-
2014
- 2014-08-06 GB GBGB1413913.3A patent/GB201413913D0/en not_active Ceased
-
2015
- 2015-08-06 CA CA2955056A patent/CA2955056A1/en not_active Abandoned
- 2015-08-06 EP EP15747487.5A patent/EP3193926B1/en active Active
- 2015-08-06 BR BR112017002342-3A patent/BR112017002342A2/en not_active Application Discontinuation
- 2015-08-06 MX MX2017001599A patent/MX2017001599A/es unknown
- 2015-08-06 US US15/501,710 patent/US10100119B2/en active Active
- 2015-08-06 WO PCT/EP2015/068208 patent/WO2016020502A1/en not_active Ceased
- 2015-08-06 AU AU2015298852A patent/AU2015298852A1/en not_active Abandoned
- 2015-08-06 KR KR1020177004417A patent/KR20170039685A/ko not_active Withdrawn
- 2015-08-06 CN CN201580042011.9A patent/CN107074946B/zh active Active
- 2015-08-06 JP JP2017506267A patent/JP6827411B2/ja active Active
-
2018
- 2018-08-22 US US16/109,017 patent/US10562971B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530692A5 (en:Method) | ||
| JP7295146B2 (ja) | 抗－ｒｏｒ１抗体およびその用途 | |
| US10781256B2 (en) | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies | |
| TWI701259B (zh) | ４﹘１ｂｂ抗體及其製備方法和應用 | |
| JP6548696B2 (ja) | ヒト抗ｉｌ−３３中和モノクローナル抗体 | |
| JP5745854B2 (ja) | Ｔｌ１ａに対するヒト化抗体 | |
| JP2020510422A5 (en:Method) | ||
| JP2019116474A5 (en:Method) | ||
| JP2017519501A5 (en:Method) | ||
| KR20190140943A (ko) | 항-cd33 항체 제제 | |
| JP2014507138A5 (en:Method) | ||
| JP2018512175A5 (en:Method) | ||
| JP7257971B2 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2012012402A5 (en:Method) | ||
| CN103097416B (zh) | 人源化il-25抗体 | |
| JP2020505386A (ja) | 抗ｐｄ−１抗体およびその使用 | |
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| JP2012523848A5 (en:Method) | ||
| JP2008529489A5 (en:Method) | ||
| JP2019511201A5 (en:Method) | ||
| WO2020154150A1 (en) | High affinity monoclonal antibodies targeting glypican-1 and methods of use | |
| JP2020534012A5 (en:Method) | ||
| JP2014515600A5 (en:Method) | ||
| TWI688575B (zh) | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 | |
| JP2023548535A (ja) | インターロイキン３６ｒを標的とする抗体、その調製法と応用 |